 |
|
|
|
 |
|
|
| Article 1 to 7 out of 7 concerning ARTEMIS Pharmaceuticals GmbH
|
-
ARTEMIS and Taconic Acquire Chemical Genetics Technology From CGI Pharmaceuticals, Inc.
(04 May 2007)
Taconic Farms, Inc. and ARTEMIS Pharmaceuticals GmbH announced that they have jointly acquired the worldwide rights to the ASKA technology from CGI Pharmaceuticals Inc. ASKA technology is based on the replacement of a normal kinase with a ...
-
ITI Life Sciences Generates First Commercial Licence
(30 Oct 2006)
CXR Biosciences and Artemis Pharmaceuticals granted licence to exploit novel transgenic models in drug discovery and development
ITI Life Sciences announced that it has reached its first commercial milestone with the grant of a licence to CXR Biosciences and Artemis Pharmaceuticals to use new technology generated in its R&D programme developing new predictive transgenic ...
-
CIBASA and ARTEMIS Pharmaceuticals sign Agreement for Marketing of Cancer Stem Cell Technology for Drug Research
(17 Nov 2005)
ARTEMIS Pharmaceuticals GmbH (Cologne, Germany) and the Center for Applied Molecular Research Salamanca (CIBASA), a Spanish biotechnology company, today announced the signing of a worldwide marketing agreement. Under the terms of the contract ...
-
New £5.5 million R&D Programme to develop new predictive models for preclinical drug development
(28 Feb 2005)
ITI Life Sciences , together with CXR Biosciences and Artemis Pharmaceuticals announced the launch of a new £5.5 million R&D programme to develop new screening and safety models to more accurately predict the effects of drug compounds and their ...
-
Artemis Pharmaceuticals and Schering AG Cooperate in Mouse Genetics
(30 Nov 2004)
Artemis Pharmaceuticals GmbH, Cologne and Schering AG, Berlin, have signed a cooperation agreement in mouse genetics and genomics. As part of this cooperation, Artemis will generate various genetically engineered mouse models for Schering. Schering ...
-
Biovitrum Sign Research Collaboration Agreement with Artemis Pharmaceuticals
(09 Jul 2004)
Biovitrum AB and Artemis Pharmaceuticals GmbH, Cologne, have signed a Research Services Agreement concerning the generation of RNAi-modified transgenic mice for the in vivo functional analysis of selected disease related genes.The application of ...
-
Artemis Pharmaceuticals and Merck Collaborate to Develop Customized Mouse Models
(12 Jun 2002)
Cologne, Germany, June 10, 2002. Artemis Pharmaceuticals GmbH, a wholly-owned subsidiary of Exelixis, Inc. has established a collaboration with Merck & Co., Inc. for the creation of customized genetically engineered mouse models of disease based on ...
Additional information
ARTEMIS Pharmaceuticals GmbH
Köln, Germany
Company
|
|
|
|
|
|
Top
